Chemomab Therapeutics Financials - Benzinga

Chemomab Therapeutics Ltd

CMMBNASDAQ

Trade with Public

Trade with Public

$1.90

-0.02-1.04%

At close: Aug 13, 5:00 PM EST

$1.92

0.021.05%

After Hours: 9:14 AM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Stock Report

Chemomab Therapeutics Financials

Chemomab Therapeutics (CMMB) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Chemomab Therapeutics Q1 EPS $(0.24) Beats $(0.31) Estimate

Chemomab Therapeutics (NASDAQ:CMMB) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.31) by 22.58 percent. This is a 57.14 percent increase over losses of $(0.56) per share

Benzinga Newsdesk

PRO
Chemomab Therapeutics Q4 EPS $(0.24) Beats $(0.40) Estimate

Chemomab Therapeutics (NASDAQ:CMMB) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.40) by 40 percent. This is a 62.5 percent increase over losses of $(0.64) per share from

Benzinga Newsdesk

PRO
Chemomab Therapeutics Q3 EPS $(0.28) Beats $(0.40) Estimate

Chemomab Therapeutics (NASDAQ:CMMB) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.40) by 30 percent. This is a 65 percent increase over losses of $(0.80) per share from

Benzinga Newsdesk

PRO
CORRECTION: Chemomab Therapeutics Q2 EPADS $(0.09) Misses $(0.07) Estimate

Chemomab Therapeutics (NASDAQ:CMMB) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.07) by 20 percent. This is a 592.31 percent decrease over losses of $(0.01) per share

Benzinga Newsdesk

PRO
UPDATE: Chemomab Therapeutics Q1 EPADS $(0.14) Misses $(0.10) Estimate

Benzinga Newsdesk

PRO
Chemomab Therapeutics Q4 EPS $(0.008) vs $(0.013) YoY

Benzinga Newsdesk